Accelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering

Accelerate Diagnostics Announces Closing of $79.3 Million Upsized Offering
share Share

Accelerate Diagnostics, Inc. announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock, upsized from the original share offering of 2,500,000 shares of common stock, at a previously disclosed public offering price of $28.85 per share. The gross proceeds to Accelerate Diagnostics from the offering are approximately $79.3 million before deducting underwriting commissions and discounts, and estimated offering expenses payable by the company. In addition, Accelerate Diagnostics has granted the underwriters of the offering a 30-day option to purchase up to an additional 412,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Accelerate Diagnostics anticipates using the net proceeds from the offering for general corporate purposes and to fund commercialization efforts.


J.P. Morgan Securities LLC is acting as lead book-running manager for the offering. William Blair & Company, L.L.C. and Piper Jaffray & Co. are also acting as joint book-running managers. BTIG, LLC is acting as lead manager for the offering.


An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on April 13, 2017. The offering is being made solely by means of a prospectus. A copy of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at [email protected]; from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at [email protected]; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at [email protected].


This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


Source & Image Credit: Accelerate Diagnostics, Inc.


«« To Withhold or Withdraw Life-support in the ICU


New-onset Diabetes After Acute and Critical Illness »»

Published on : Mon, 15 May 2017



Related Articles
Accelerate Diagnostics Announces Sizeable Release of Data at ASM Microbe 2017

Accelerate Diagnostics, Inc. has announced that new data from 11 healthcare institutions covering more than 1,200 samples will... Read more

Hospital de La Princesa shortens antibiotic adaptation treatment for severe sepsis using a new diagnosis tool

In positive blood cultures, the Accelerate Pheno TM system identifies the agent causing the infection in 90 minutes and around... Read more

Hampshire hospitals NHS foundation trust pioneers use of diagnostic tools for earlier optimisation of antibiotic therapy for sepsis patients

… Antimicrobial Susceptibility Testing (AST) times reduced from days to hours….   Hampshire Hospitals NHS Foundation Trust... Read more

public offering,Accelerate Diagnostics,common stock,financial report Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock, upsized from the original share offering of 2,500,000 shares of common stock

No comment


Please login to leave a comment...

Highlighted Products